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Introduction
Proteinuria has a high prevalence in dogs with chronic 
kidney disease (CKD) and several studies have shown its 
role in promoting the progression of renal disorders (Jacob 
et al., 2002; D’Amico and Bazzi, 2003). In endemic 
areas for vector-borne diseases, such as leishmaniosis, 
the prevalence of proteinuric CKD has been reported 
to vary between 30.2% and 52.7% (Cortadellas et al., 
2006). Among dogs at risk for developing proteinuric 
CKD, other than those living or having lived in endemic 
areas for vector-borne disease, there are also some breeds 
that are genetically predisposed to develop proteinuric 
glomerulonephritis (Chew et al., 2011; Harley and 
Langston, 2012). Early identification and treatment of 
proteinuria is important in dogs, not only because of the 
high prevalence of proteinuric CKD, but also because 
its management allows to slow the progression of CKD, 
thus leading to decrease the risk of uremic crisis, and 
kidney-related mortality (Jacob et al., 2002; Jacob et al., 
2005; Brown et al., 2013). Angiotensin-converting 
enzyme (ACE)-inhibitors and dietary intervention are 
the major cornerstones of treatment in proteinuric CKD 
dogs; they have been shown to minimize clinical signs 
of uremia and, at least for the latter, to maintain optimal 
body conditions (Grauer et al., 2000; Tenhündfeld et al., 
2009; Brown et al., 2013; Cortadellas et al., 2014). In 
order to limit the accumulation of nitrogenous waste 
products and to slow the progression of CKD, dietary 
protein restriction has been recommended for CKD dogs 
in International Renal Interest Society (IRIS) stages 1 
with urine protein-to-creatinine ratio (UPC) >0.5 (IRIS 
substage P) and in any case in IRIS stages 2, 3 and 4 
(Jacob et al., 2002; Brown et al., 2013; Cortadellas et al., 
2014; IRIS Guidelines). Nonetheless, in some dogs, anti-
proteinuric treatments (renal diet administered along with 
ACE-inhibitors) do not provide substantial reduction of 
proteinuria (Brown et al., 2013; Bugbee et al., 2014). 
Previously published study (Cortadellas et al., 2014) 
demonstrated a doubtful antiproteinuric efficacy of some 
ACE-inhibitors. Whether different ACE-inhibitors have 
distinct antiproteinuric and kidney protective effects is 
unknown; it is possible that renal diets and enalapril or 
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Abstract
Treating proteinuria in dogs reduces the progression of chronic kidney disease (CKD); renal diets and angiotensin -
converting enzyme (ACE)-inhibitors are cornerstones of treatment. Whether different ACE-inhibitors have distinct 
kidney protective effects is unknown; it is therefore hypothesized that renal diets and enalapril or benazepril have 
different beneficial effects in proteinuric CKD dogs. Forty-four dogs with proteinuric CKD (IRIS stages 1-4) were 
enrolled in the study and were fed renal diet for 30 days. Thereafter, they were randomly assigned to one of 2 groups. 
Dogs in group A (n=22) received enalapril (0.5 mg/kg, q12h) and in group B (n=22) benazepril (0.5 mg/kg, q24h); 
in both groups, dogs were fed the same renal diet. After randomization, dogs were monitored for 120 days. Body 
weight and body condition score (BCS), serum concentrations of creatinine, blood urea nitrogen (BUN), albumin 
and total proteins, and urine protein-to-creatinine (UPC) ratio were compared at different time-points. After 30 days 
of renal diet, creatinine, BUN and UPC ratio decreased significantly (p<0.0001). Compared to randomization, body 
weight, BCS, albumin, total proteins, creatinine and BUN did not vary during follow-up in the 44 dogs and differences 
between group A and B were not observed. However, the UPC ratio of group A at day 60, 90 and 150 was significantly 
lower than in group B and compared to randomization (p<0.05). In group B it did not vary overtime. It is concluded 
that the renal diet is beneficial to decrease creatinine, BUN and UPC ratio in proteinuric CKD dogs. Enalapril further 
ameliorates proteinuria if administered along with renal diet.
Keywords: ACE-I, CKD, Diet, Proteinuria.
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benazepril provide different advantages in proteinuric 
CKD dogs. Moreover, in dogs with severe proteinuric 
glomerulonephritis (unresponsive to anti-proteinuric 
treatment) renal diets may not adequately meet 
protein requirements, thus leading to malnutrition and 
hypoalbuminemia, both frequent in dogs with proteinuric 
CKD. Furthermore, malnutrition and hypoalbuminemia 
have been associated with increased morbidity and risk 
of mortality (Remillard et al., 2001; Cave, 2010; Parker 
and Freeman, 2011).
In light of these premises, proteinuric CKD dogs were 
included to investigate the short-term effect of renal 
diet given alone and the medium-term effect of the 
same renal diet combined with the administration of the 
ACE-inhibitors enalapril or benazepril; their efficacy 
on body weight and BCS, on serum concentrations of 
creatinine, blood urea nitrogen (BUN), albumin and 
total proteins, and on the UPC ratio was assessed.
Materials and Methods
Animals and inclusion criteria
Dogs of any age and sexual status were considered 
for the present study if affected by naturally occurring 
CKD in IRIS stages 1, 2, 3 and 4 and if proteinuria 
was documented (UPC ratio >0.5; IRIS substage P) 
(IRIS Guidelines). The database at admission consisted 
of history, physical examination including body 
weight and body condition score (BCS; based on 
a 1 to 5 scale with 3 being optimal) (Thatcher et al., 
2010), hematologic and serum biochemical profile, 
urinalysis, UPC ratio, immunofluorescence antibody 
titer (IFAT) for Leishmania infantum, Ehrlichia canis 
and Anaplasma phagocytophilum, and non-invasive 
determination of systolic arterial pressure.
Dogs presenting inflammatory diseases of the 
genitourinary tract, cardiac disease, neoplasia or 
endocrinopathies, severe hypertension (≥180 mmHg) 
(IRIS Guidelines) or anemia with hematocrit <25% 
and/or hemoglobin <10.0 g/dL, and seropositive for 
Leishmania infantum, Ehrlichia canis or Anaplasma 
phagocytophilum with associated clinical or laboratory 
signs other than UPC ratio >0.5 were excluded. Dogs 
that had received ACE-inhibitors, angiotensin II 
receptor blockers, or corticosteroids during the 12 weeks 
previous to admission were also excluded. Furthermore, 
to be enrolled, dogs had to show stable renal function, as 
defined by serum creatinine concentrations that did not 
increase or decreased by more than 15% within 4 weeks 
from admission; a maximum variation of 0.4 mg/dL 
have been considered indicative of stable renal function 
(Jacob et al., 2002; IRIS Guidelines). Dogs were 
recruited if an informed consent form to participate in 
the study was signed by the owners.
Study design
Following admission, all dogs initially included 
were fed a renal diet (Prescription Diet Canine k/D, 
Hill’s Pet Nutrition, Topeka, KS) for 30 days. After 
30 days, dogs were re-evaluated and allocated to 
one of the two following groups: group A receiving 
oral enalapril (Enacard, Merial, Milan, Italy) at 
0.5 mg/kg, q12h, plus renal diet, and group B 
receiving oral benazepril (Fortekor, Novartis Animal 
Health, Milan, Italy) at 0.5 mg/kg, q24h, plus the 
same renal diet. Randomization was achieved with a 
software (MedCalc®, Version 11.3.0.0 (http://www.
medcalc.com/)). Either enalapril or benazepril were 
administered using the recommended dosages of their 
commercial claims. At the time of the study, both drugs 
were registered for use in proteinuric CKD dogs in 
the country where the study was performed (Italy). 
Every dog included in the study was examined at day 
0 (admission), at day 30 (randomization) and at days 
45, 60, 90 and 150. The list of exams performed during 
each evaluation is reported in Table 1. The listed exams 
were used to evaluate the effect of treatment and to 
rule-out laboratory abnormalities caused by one of the 
infectious diseases stated above.
Blood samples
Venous blood samples (5.0 mL each) were collected 
in overnight fasted dogs and every sample was placed 
in tubes containing K3-EDTA (1.5 mL) and in tubes 
without anticoagulant (3.5 mL). Serum was obtained 
within 30 minutes from collection and stored along 
with samples in K3-EDTA tubes at 4°C. Hematologic 
and serum biochemical profiles were determined 
within 24 hours with standard methods (BC-2800Vet, 
MINDRAY, Mindray Co., Shenzhen, China; Cobas 
Table 1. Time schedule and exams performed at each 
evaluation in all dogs.
 Exams Time point (days)
0 30 45 60 90 150
Body weight X X X X X
Body condition score X X X X X
Systolic arterial pressure X X X X X
Hematology* X X X
Biochemical profile 1** X X X
Biochemical profile 2*** X X X
Serology† X X
Urinalysis‡ X X X X X X
*: Including erythrocyte, leukocytes and platelet counts, 
hematocrit, hemoglobin, **: Including creatinine, BUN, 
alanine aminotransferase, alkaline phosphatase, bilirubin, 
cholesterol, albumin, total proteins, albumin to globulin ratio, 
serum electrophoresis, ionized and total calcium, phosphorus, 
sodium, potassium, and chloride, ***: Including creatinine, 
BUN, albumin, total proteins, albumin to globulin ratio, 
ionized and total calcium, phosphorus, sodium, potassium, 
chloride, †: Including IFAT for Leishmania infantum, 
Ehrlichia canis and Anaplasma phagocytophilum, ‡: Including 
chemical-physical and sediment examination, and UPC ratio
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Mira, Roche Diagnostic, Basel, Switzerland). Regarding 
the biochemical profile, based on the reference range 
for serum albumin at our laboratory (2.8-3.8 g/dL), 
severe hypoalbuminemia was arbitrarily considered 
if the concentration was <2.0 g/dL. Dogs with severe 
hypoalbuminemia received oral acetylsalicylic acid at 
2.0 mg/kg, q24h, to prevent thrombosis (Brown et al., 
2013; Dudley et al., 2013).
Urine samples
To collect urines, ultrasound-guided cystocentesis 
were performed in every dog using a 5.0 mL syringe 
connected to a 23-gauge needle. Before analysis, urine 
samples were placed in a 10.0 mL, sterile, evacuated 
collection tube. Urines were stored at room temperature 
and e xamined within 4 hours from collection. Urine 
sediment was obtained by centrifugation (10 minutes 
at 900 × g) of 5.0 mL of urine, followed by removal of 
4.5 mL of supernatant, and resuspension of the remaining 
0.5 mL of urine. A sample of 12 μL of the resuspended 
sediment was microscopically assessed. Erythrocytes 
and leukocytes were expressed as mean number of 
cells/10 high-power fields (hpf, 40× magnification). 
Urine sediment with bacteriuria, and/or >5 erythrocytes/
hpf or leukocytes/hpf, was considered indicative of 
inflammation (active sediment) and excluded for the 
UPC ratio measurement (Beatrice et al., 2010). The 
supernatant was transferred into separate tubes and 
stored at –20°C to determine urine protein and creatinine 
concentrations within 7 days. To calculate the UPC 
ratio, protein concentration (mg/dL) was measured with 
pyrogallol red and creatinine (mg/dL) using the Jaffé 
method (Real Time Diagnostic System); measurements 
were performed with an automated spectrophotometer 
(Cobas Mira, Roche Diagnostic, Basel, Switzerland). 
Based on a previous study (Rossi et al., 2012), according 
with laboratory standard operating procedures (SOP), 
urine samples were manually diluted 1 to 20 with 
distilled water to fit linearity of the method. Occasionally, 
particularly concentrated urine samples were further 
diluted to 1:100 to fit the linearity of the method. Quality 
control was performed before any work session with 
two levels (normal and high) of control serums (Normal 
Control Serum and Pathological Control Serum) for 
creatinine. For urinary protein a specific control with 
bovine albumin (100 mg/dL) was used.
Statistical analysis
To study the effect of the renal diet on serum 
concentrations of creatinine and BUN, and on the UPC 
ratio, values were compared between admission and 
after 30 days with the Wilcoxon matched pairs test. 
To verify whether characteristics of the two groups 
were similar at randomization (i.e. after 30 days of 
renal diet and before introduction of ACE-inhibitors), 
age, body weight, serum concentrations of albumin, 
total proteins, creatinine and BUN, and the UPC ratio 
were compared with the Mann-Whitney test followed 
by Bonferroni post hoc test. Sex distribution and BCS 
were compared between groups with Fisher’s exact 
test. To study the effect of enalapril or benazepril 
administered along with the renal diet, on serum 
concentrations of albumin, total proteins, creatinine 
and BUN, and on the UPC ratio data were analyzed 
using an unequally spaced repeated measures model 
(Littell et al., 1998), assuming as covariance structure 
a spatial power law on the repeated individual values 
at different times (day 30, 45, 60, 90 and 150) with 
baseline values as covariates. The model included the 
fixed effects of treatment (group A vs. B), time and 
their interaction; the dog was the repeated random 
factor. For statistical differences showed by time and 
time × treatment effects, all pairwise contrasts were 
also calculated and corrected with Bonferroni post hoc 
test. Normality of residuals was evaluated by Shapiro-
Wilk test and values ≥0.9 were considered as normal. 
Independence of residuals was graphically checked. 
Statistical significance was considered for p<0.05. Data 
were analyzed with softwares (GraphPad QuickCalcs 
calculator (2002-2005) by GraphPad Software, San 
Diego, CA; SAS 9.3, SAS Institute, Cary, NC).
Results
Animals
Forty-four dogs were included in the study. Median age 
at admission was 5 years (range: 1-19 years), median 
body weight was 26 kg (range: 3.8-69), and the median 
BCS was 3 (range: 2-4). Twenty-one dogs were intact 
males, 13 were spayed females, 6 were intact females 
and 4 were castrated males. Eight dogs were cross-breed 
and 36 were pure-breed, including 9 Boxers, 4 Yorkshire 
Terriers, 3 Cocker Spaniels and Golden Retrievers, 
2 Bernese Mountain dogs and Rottweilers and, one 
each of American Staffordshire, Beagle, Bolognese, 
Italian Bracco, Bull Terrier, Czechoslovakian Wolfdog, 
Dachshund, Fox Terrier, German Shepherd, Irish Setter, 
Scottish Terrier, Samoyed and Weimaraner.
Effects of renal diet
After 30 days of renal diet, serum creatinine and BUN, 
and UPC ratio decreased (Fig. 1). In particular, median 
creatinine at admission was 2.4 mg/dL (range: 1.0-9.1) 
and after 30 days it was 2.2 mg/dL (range: 0.6-7.5) 
(p<0.0001); creatinine decreased in 38 dogs (86.4%) 
and increased in the remaining 6 (13.6%). Median BUN 
at admission was 56 mg/dL (range: 18-148) and after 
30 days it was 47 mg/dL (range: 10-108) (p<0.0001); 
BUN decreased in 41 dogs (93.2%) and increased in 
the remaining 3 (6.8%). Median UPC ratio at admission 
was 2.9 (range: 0.8-19.8) and after 30 days it was 2.2 
(range: 0.6-14.4) (p<0.0001); UPC ratio decreased in 42 
dogs (95.5%) and increased in the remaining 2 (4.5%).
Effects of enalapril or benazepril associated with 
renal diet
Randomization performed after 30 days of renal diet 
and before introduction of ACE-inhibitors showed 
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that age, body weight, BCS, serum concentrations of 
albumin, total proteins, creatinine and BUN, and the 
UPC ratio did not differ between dogs allocated to 
group A or B (Table 2).
Twenty-two dogs were initially included into group A 
and received enalapril. Twenty-two were included into 
group B and received benazepril. Both groups were 
fed the same renal diet. In group A, 3 of the 22 dogs 
(13.6%) died during the study period; 2 of them died 
between 60 and 90 days following the start of the study 
and 1 between 90 and 150 days. In the group B, 2 of 
the 22 dogs (9.1%) died, 1 between 60 and 90 days and 
1 between 90 and 150 days following the start of the 
study. In all 5 dogs, death was due to the progressive 
worsening of CKD; of the same dogs, after 30 days of 
renal diet, 5 had a decrease of creatinine, 4 of BUN 
and 5 of the UPC ratio. Furthermore, 3 dogs (13.6%) in 
group B were missed at follow-up visits, 2 between 60 
and 90 days and 1 between 90 and 150 days after the 
start of the study.
Serum concentrations of albumin, total proteins, 
creatinine and BUN, and UPC ratio of dogs in groups A 
and B at randomization and during follow-up are 
reported in Table 3. Serum concentrations of albumin, 
total proteins, creatinine and BUN did not vary during 
the follow-up period to any significant degree in the 
44 dogs grouped together, as compared to randomization 
(day 30). Furthermore, for the same parameters, 
differences between groups A and B were not observed 
during treatment. Dogs in group A had significantly 
lower UPC ratio at day 60 (p<0.05), day 90 (p<0.01) 
and day 150 (p<0.05) as compared to randomization 
(Table 3), whereas dogs in group B had not different UPC 
Table 2. Comparison of variables used to assess adequacy of 
matching of dog groups. Values are reported as median and 
range or as number of dogs and frequency.
Variable Group A Group B p-value
Age (years) 6 (2-12) 4 (1-19) 0.916
Sex 1.000
Female 3 (13.6%) 3 (13.6%)
Spayed female 7 (31.9%) 6 (27.3%)
Male 9 (40.9%) 12 (54.5%)
Castrated male 3 (13.6%) 1 (4.6%)
Body 
weight (kg)
25.9 (4.2-57) 27 (3.8-69) 0.916
BCS 1.000
2 6 (27.3%) 8 (36.4%)
3 15 (68.2%) 12 (54.5%)
4 1 (4.5%) 2 (9.1%)
Albumin (g/dL) 2.7 (1.7-3.5) 2.9 (1.6-4.0) 0.350*
Total proteins
(g/dL)
5.7 (4.8-7.0) 6.4 (4.9-8.5) 0.084*
Creatinine
(mg/dL)
1.8 (0.6-3.4) 2.3 (1.0-3.3) 0.117
BUN (mg/dL) 42 (12-72) 49 (10-108) 0.110
UPC ratio 2.3 (0.7-11.5) 2.0 (0.6-14.4) 0.404
*: p-value corrected with Bonferroni’s post hoc test
Fig. 1. Serum concentrations of creatinine (a) and BUN (b), and UPC ratio (c) in all dogs before any treatment (day 0) and after 
one month of renal diet (day 30).
c
ba
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ratio at each time point during follow-up compared to 
randomization. Dogs in group A had significantly lower 
UPC ratio than dogs in group B at day 60 (p<0.05), 90 
(p<0.05) and 150 (p<0.05) (Fig. 2).
Discussion
Because persistent renal proteinuria in dogs has 
been associated with a poorer prognosis (Harley and 
Langston, 2012) its treatment is recommended in order 
to improve quality of life and survival time. For this 
purpose, the potential beneficial effects of renal diet and 
of the ACE-inhibitors enalapril and benazepril in dogs 
with proteinuric CKD were assessed in the present study.
With regard to dietary management, we substantiated 
the beneficial effect of using renal diet in proteinuric 
CKD dogs. Indeed, during the first 30 days of the trial, 
the enrolled dogs were managed with the renal diet 
but did not receive any medication and a significant 
improvement of serum concentrations of creatinine and 
BUN, as well as the UPC ratio was observed compared 
to baseline. Main characteristics of the selected diet, 
which are the key points of the dietary management 
(Roudebush et al., 2010; Polzin, 2013) are protein 
restriction with high biological value, phosphorus 
and sodium reduction and supplementation with ω-3 
polyunsaturated fatty acids (PUFAs). Among them, 
content and quality of proteins as well as phosphorus 
and sodium restriction seem to be the most important 
aspects to consider in proteinuric CKD dogs, whereas 
the effect of PUFAs is yet not fully known and deserves 
further investigation (Roudebush et al., 2010; Brown 
et al., 2013).
For the present trial, the ACE-inhibitors enalapril and 
benazepril were administered using the recommended 
dosages of their commercial claims. The group 
treated with enalapril showed a significant reduction 
of the UPC ratio after 30 days of treatment (60 days 
from the beginning of the study); however, the group 
treated with benazepril did not show ameliorations of 
the UPC ratio, at any time. One recent study showed 
Table 3. Serum concentrations of albumin, total proteins, creatinine and BUN, and UPC ratio of dogs  in groups A and B at 
randomization (30 days) and follow-up evaluations. Median and range are reported.
Variable Time point (days)
30 45 60 90 150
Albumin (g/dL)
Group A 2.6 (1.7-3.5) 2.7 (1.6-3.4) 2.6 (1.9-3.4) 2.7 (1.9-3.5) 2.7 (2.1-3.4)
Group B 2.9 (1.6-4.0) 2.8 (1.7-3.6) 2.8 (1.8-3.6) 2.8 (2.0-3.3) 2.8 (1.8-3.1)
Total proteins (g/dL)
Group A 5.7 (4.8-7.0) 5.8 (4.8-6.7) 5.8 (5.0-6.8) 5.9 (5.2-6.8) 5.8 (5.1-7.0)
Group B 6.4 (4.9-8.5) 6.3 (4.8-7.9) 6.3 (5.0-7.7) 6.0 (5.2-7.7) 6.2 (5.1-6.9)
Creatinine (mg/dL)
Group A 1.8 (0.6-3.4) 1.8 (0.7-3.7) 1.6 (0.8-3.9) 1.6 (0.9-4.3) 1.5 (0.9-3.4)
Group B 2.3 (1.0-3.3) 2.4 (1.0-5.0) 2.3 (0.8-5.5) 2.3 (0.9-7.5) 2.4 (0.9-5.0)
BUN (mg/dL)
Group A 42 (12-72) 42 (17-66) 40 (13-89) 37 (15-89) 36 (16-67)
Group B 49 (10-108) 49 (19-112) 50 (16-143) 50 (20-100) 50 (20-85)
UPC
Group A 2.3 (0.7-11.5) 2.3 (0.8-8.0) 1.6 (0.4-5.6)* 1.2 (0.3-8.9)† 1.2 (0.5-4.5)*
Group B 2.0 (0.6-14.4) 2.2 (0.6-9.2) 2.2 (0.5-9.8) 1.8 (0.6-9.0) 1.9 (0.6-9.2)
Significant differences between follow-up evaluations and randomization within groups: *: p<0.05; †: p<0.01
Fig. 2. UPC ratio in dogs receiving enalapril and renal diet 
(group A, black dots) or benazepril and renal diet (group B, 
white dots) at randomization (day 30) and follow-up. Median 
values and interquartile ranges are shown. Significant 
differences between group A and B are depicted with asterisks 
(p<0.05).
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that benazepril might not be effective in reducing renal 
proteinuria in dogs (Cortadellas et al., 2014). However, 
as proposed by the same authors, the lack of efficacy of 
benazepril in their investigation might have been due to 
the drug dosage used (Cortadellas et al., 2014). Indeed, 
based on studies in humans, increasing the dosage of 
ACE-inhibitors can improve the antiproteinuric effect, 
possibly suggesting that higher dosages of benazepril 
might also be beneficial to decrease proteinuria in 
CKD dogs (Weinberg et al., 2001; Tylicki et al., 
2012). On the other hand, another investigation in dogs 
showed a reduction of the UPC ratio associated with 
the administration of benazepril (Tenhündfeld et al., 
2009). However, comparison between our results and 
those of Tenhündfeld et al. (2009) is difficult because 
they had three different groups of only 10 dogs, treated 
with placebo, benazepril and benazepril plus heparin, 
which were not homogeneous for UPC ratio at the 
time treatment was started. Furthermore, they observed 
a beneficial effect on UPC ratio only by day 180 for 
dogs in the benazepril group and by day 90 for dogs 
in the benazepril plus heparin group. Therefore, if an 
effect of benazepril exists on proteinuria, it would 
likely be delayed compared to that achieved with 
enalapril, questioning the real benefit of benazepril 
to treat proteinuric CKD dogs based on the current 
recommended dosages.
In the present study, the significant reduction of UPC 
ratio in the group treated with enalapril was evident by 
30 days of therapy, whereas no significant amelioration 
was observed if tested after only 15 days of treatment 
with the ACE-inhibitor. This result may provide 
useful information for the monitoring of proteinuric 
CKD dogs in clinical practice. To assess the potential 
favorable effect of enalapril to control proteinuria in 
dogs, the UPC ratio should be evaluated after 30 days 
of treatment; therefore, absence of improvement at 
15 days should not be regarded as indicative of lack of 
efficacy.
During the study period, none of the dogs developed 
severe hypertension and thus needed to receive 
amlodipine or other anti-hypertensive treatments. The 
fact that blood pressure did not increase throughout the 
study may be due to the limited duration of the trial, or 
to the administration of ACE-inhibitors.
Some limitations of the study need to be mentioned, 
including the relative small sample size, the lack of 
blinding and of renal biopsies. The risk associated with 
lack of masking was minimized by randomization and 
by excluding statistical differences between the groups 
at the time the ACE-inhibitors were started. Absence 
of renal histology did not allow excluding that, in 
some dogs, proteinuria was primarily due to tubular or 
tubulointerstitial damage, rather than being of glomerular 
origin. However, if this was the case, it is likely that 
dogs with tubular or tubulointerstitial damage were 
evenly distributed between groups. In addition, dogs 
with severe hypoalbuminemia (<2 g/dL) received oral 
acetylsalicylic acid. As hypothesized by some authors 
(Grauer et al., 2000; Cortadellas et al., 2014), low 
dosages of acetylsalicylic acid have a beneficial effect 
on proteinuria in dogs with glomerulonephritis and, 
therefore, its use might have partly biased the results of 
the study. Nonetheless, the potential beneficial effect of 
acetylsalicylic acid was likely similar between groups 
as the frequency of dogs with severe hypoalbuminemia 
that received it did not differ.
In conclusion, the administration of renal diet 
ameliorates serum creatinine, BUN and UPC ratio, 
and adding enalapril decreases the UPC ratio further 
in dogs with proteinuric CKD. Using benazepril, at the 
present dosage and for 120 days, was not beneficial 
compared with enalapril. Future studies are needed 
to verify the effect of benazepril over longer periods 
or at higher dosages in dogs with proteinuric CKD, 
or that of angiotensin II receptor blockers or PUFAs, 
administered along with renal diet.
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